Board of Directors
Peter Buhl Jensen
Chairman of the Board since 2021
Peter Buhl Jensen (born 1955) is MD specialist in internal medicine and has a DMSc. Peter Buhl Jensen has a strong combination of commercial experience and medical expertise, especially in oncology, and has written over 120 scientific articles. Peter Buhl Jensen is the founder of TopoTarget A/S, Allarity Therapeutics (formerly Oncology Venture) and Medical Prognosis Institute A/S, as well as several successful ventures in the Life Science sector. Peter Buhl Jensen backed TopoTarget’s IPO in 2005 and secured EMA and FDA approval of the company’s first product, Savene©/Totect©. Peter Buhl Jensen was also involved in the IPO of Allarity Therapeutics and the Medical Prognosis Institute. In addition, Peter Buhl Jensen is behind the development of the drug Belinostat, which was approved by the FDA in the summer of 2014. Peter Buhl Jensen has leadership experience from TopoTarget, where he led approximately 140 employees, as well as from Aalborg University Hospital where he was a senior consultant at the Department of Oncology and led approximately 280 employees. Furthermore, Peter Buhl Jensen is an adjunct professor of clinical oncology at the University of Copenhagen and has been a consultant physician and led LEMO (Laboratory of Experimental Medical Oncology) at Rigshospitalet University Hospital in Copenhagen.
Other ongoing assignments: Board member of Cobis A/S, Symbion A/S and Symbion Foundation. CEO of Symbion A/S. Member of the Management Board (Executive Board) of Buhl Krone Holding ApS.
Holdings in the company: 0 Shares
Position of dependency: Independent in relation to the company and its management, and in relation to major shareholders.
Christopher Bravery
Board member since 2021
Christopher Bravery (born 1967) holds a PhD in immunology from Imperial College, London, and a bachelor’s degree in biochemistry. Christopher Bravery is a researcher with over 20 years of experience in the pharmaceutical industry and with a primary focus on advanced therapies including Advanced Therapy Medicinal Products (ATMP),cells, gene and tissue products and other products for regenerative medicine. Christopher Bravery has deep knowledge of preclinical regulatory science from work in both the biotechnology industry and work at the regulatory authority. Christopher Bravery also has a good understanding of clinical trials in the EU, as well as licensing and post-licensing requirements from experience as a reviewer at the Medicines and Healthcare Products Regulatory Agency (MHRA) and the European Medicines Agency. During his time at the MHRA, Christopher Bravery was involved in the national implementation of the Regulation of the European Parliament and of the Council on advanced therapy medicinal products and has also been active on the European Medicines Agency’s Committee on Medicinal Products for Human Use’s Working Group on Cell Products.
Other ongoing assignments: CEO of Consulting on Advanced Biologicals Ltd.
Holdings in the company: 0 Shares
Position of dependency: Independent in relation to the company and its management, and in relation to major shareholders.
Fredrik Tiberg
Board member since 2021
Fredrik Tiberg (born 1963) holds a MSc in Chemical Engineering from Lund University of Technology and a PhD in Physical Chemistry at Lund University. Fredrik Tiberg has extensive experience from the biotechnology and pharmaceutical industry. He has since 2003 served as President & CEO, Head of R&D at Camurus AB, where he is also a member of the board. Previous roles include CEO of Heptahelix AB, adjunct professor of surface chemistry at Lund University and visiting professor of physical and theoretical chemistry at the University of Oxford.
Fredrik has more than 110 publications in peer-reviewed scientific journals, is named inventor on more than 400 patents and patent applications and is a member of the Royal Swedish Academy of Engineering Sciences (IVA).
Other ongoing assignments: Board member of Camurus AB, Camurus Development AB, and Camurus Lipid Research Foundation. President and CEO of Camurus AB.
Holdings in the company: 1 618 500 Shares
Position of dependency: Independent in relation to the company and its management, and in relation to major shareholders.
Ingrid Atteryd Heiman
Board member since 2021
Ingrid Atteryd Heiman (born 1958) holds a BA in financing and industrial marketing from Lund University and an MBA in International Business from Uppsala University. She has more than 15 years of experience in the self-care market as CEO and Chairman of the trade association, Svensk Egenvård and its European counterpart as well as CEO and Chairman of the Board of Ellen AB. Ingrid Atteryd Heiman also has experience in management and board work with a focus on food, pharmaceuticals, biomedicine, Life Science and women’s health as well as experience as a board member and chairman of the board from several listed Life Science companies. Ingrid Atteryd Heiman has successfully proven her ability to strategize business development and drive profit and growth, and through her experience in management consulting in Booz (now part of PwC), has been involved in efficiency optimization, strategy development, mergers and acquisitions and IPOs. In addition, ms. Atteryd Heiman has experience in international business including business development in Europe, US and Asia, as well as work with lobbying in the European Parliament.
Other ongoing assignments: Board member of Pharmiva AB (publ), Redwood Pharma AB (publ), CarpoNovum AB, Ilama AB and VitalSigns AB.
Holdings in the company: 38 000 Shares
Position of dependency: Independent in relation to the company and its management, and in relation to major shareholders.
Marcus Larsson
CEO. Founding member. Board member since 2015
Marcus Larsson (born 1973) is a licensed physician with a degree from Lund University and a specialist in pediatrics and clinical practice at neonatal clinic, Skåne University Hospital. Marcus Larsson has a PhD in clinical physiology with a special focus on the surface structure and function of the lung and is one of the founders of Amniotics. Marcus Larsson has over 20 years of research experience in physiology and biophysical chemistry and is co-inventing several patents in the field of pharmaceuticals and biotechnology. Marcus Larsson is also Chairman of the Board of Camurus Lipid Research Foundation.
Other ongoing assignments: Board member of Deflexum AB.
Holdings in the company: 26 129 104 Shares
Position of dependency: Dependent in relation to the company and its management, and major shareholders.